LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

NCT01986426 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Melanoma
Breast Cancer
Head and Neck Cancer
Lymphoma
Triple-Negative Breast Cancer

Interventions

DRUG: LTX-315 consecutive lesions
DRUG: LTX-315
DRUG: LTX-315 + ipilimumab
DRUG: LTX-315 + pembrolizumab

Sponsor

Lytix Biopharma AS

Collaborators

[object Object]
[object Object]